Tysabri and PML: Understanding the Statute of Limitations in Michigan

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

The legacy domain of general health and science information has historically provided broad educational resources on medical conditions and therapeutic options. Within this context, public awareness of treatment-associated risks has emerged as a significant area of interest. One notable example involves the medication Tysabri, used for certain chronic conditions, and its recognized association with Progressive Multifocal Leukoencephalopathy (PML), a serious brain infection. This connection has led to legal considerations for individuals who may have been exposed to the drug and subsequently developed PML. Transitioning from this general health context to a more specific concern, the focus now shifts to occupational exposure. In mass production environments, particularly those involving pharmaceutical manufacturing or healthcare settings, workers may handle or be exposed to substances like Tysabri. This raises distinct questions about workplace safety protocols, monitoring for potential adverse effects, and the legal frameworks that apply when occupational exposure leads to health issues. For instance, in Michigan, the statute of limitations for filing claims related to Tysabri exposure and PML development becomes a critical factor for affected workers. Understanding these time limits is essential for ensuring that any legal recourse is pursued within the required timeframe, thereby protecting the rights of individuals in occupational settings.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal context of settlements and statutes of limitations, is critical. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy, balancing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in immunocompromised patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis often involves MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is crucial because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled replication in the brain. This immunosuppressive effect is particularly pronounced in patients with anti-JCV antibodies, as the virus can remain latent in the body and become active when immune defenses are compromised.

Risk Considerations and Settlement Context

The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The FDA boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers to evaluate patients at regular intervals and report cases of PML to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients have developed PML, leading to settlements and litigation. For affected patients in Michigan, settlement-related considerations include the timeline between Tysabri exposure and documented harm. PML can develop months to years after starting Tysabri, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The latency period between drug exposure and PML diagnosis is a key factor in determining when a legal claim accrues. In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For PML, this discovery date may be when symptoms first appear or when a diagnosis is confirmed. Patients who have received Tysabri and later developed PML may be eligible for compensation through settlements with the drug manufacturer. These settlements often consider the severity of disability, medical expenses, lost income, and pain and suffering. However, the statute of limitations imposes a strict deadline for filing claims, and failure to act within this period can bar recovery. Given the progressive nature of PML and the potential for delayed diagnosis, it is essential for patients and their families to seek legal advice promptly after a PML diagnosis is made.

Conclusion

The medical evidence clearly establishes that Tysabri increases the risk of PML, with identifiable risk factors and a mechanistic basis for this association. For Michigan patients who have suffered PML after Tysabri treatment, the statute of limitations is a critical legal consideration. The timeline between exposure and harm, combined with the adequacy of warnings, forms the foundation for potential settlement claims. Patients should consult with a qualified attorney to understand their rights and ensure timely action.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Michigan?

In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For PML, this discovery date may be when symptoms first appear or when a diagnosis is confirmed. It is crucial to act promptly after diagnosis to preserve legal rights.

What are the primary risk factors for developing PML while on Tysabri?

The FDA boxed warning identifies three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.